Drug-eluting stents (DESs) are commonly used for the treatment of coronary artery disease.
The evolution of the drug-eluting layer on the surface of the metal stent plays an important …

Background Paclitaxel‐coated balloon angioplasty for de‐novo coronary artery lesions
causes late lumen enlargement (LLE), however, the mechanisms and predictors of LLE …

Animal studies are often required to evaluate new cardiovascular medical devices before
they reach the market. Moreover, first-generation novel devices including aortic …

Background? After drug-coated balloon (DCB) angioplasty in patients with de novo coronary
lesions, coronary dissections can result in the continuous presence of thrombi within the …

冠状动脉支架内再狭窄成为药物涂层球囊(DCB) 的主要适应证后, DCB 越来越多地作为其一线
治疗方式. 此外, 更多的临床证据支持DCB 在原位病变中的应用, 尤其是小血管病变 …

Résumé L'insuffisance cardiaque (IC) avancée est associée à une morbidité et une mortalité
significatives. Les dispositifs d'assistance circulatoire offrent une avenue potentielle de …

Background Fully absorbable polymeric scaffolds, as a potential alternative to permanent
metallic stents, are entering the clinical field. The aim of this study is to assess the in vivo …

Coronary in-stent restenosis (ISR) has become the main indication of the drug-coated
balloon (DCB), DCB is increasingly used as a first-line treatment. In addition, more clinical …